The most valuable advertising position in most pharmacies is the two square metres beside the prescription counter — and almost nobody selling it can tell a supplier what it is actually worth. A vitamin brand paying for that endcap is buying an audience that queues, waits, and looks around for ninety seconds or more. That is a captive-attention environment most digital media buyers would pay a premium for. Yet in the majority of chains, that placement is still priced on square metres, historical habit, or whoever negotiated hardest at the annual trade terms meeting.
This is the gap pharmacy retail media exists to close. Not screens, not apps — the physical shelf itself, sold with the same evidence discipline as any other media channel: how many people passed, how many stopped, how long they looked. Suppliers in vitamins, supplements and skincare are already conditioned to buy media on impressions and engagement. The pharmacy that can produce those numbers for its own floor changes the entire commercial conversation.
Here is the uncomfortable arithmetic. When placements are priced on instinct, two failures happen simultaneously. High-traffic zones — the prescription queue, the till approach, the transition point between OTC and beauty — are chronically underpriced because nobody can prove their audience. Meanwhile, low-traffic zones get sold at similar rates, which suppliers eventually notice when their promoted skincare line moves nothing. The supplier loses trust, the pharmacy loses pricing credibility, and the next negotiation starts from a weaker position for everyone.
Compare this with how shopping centres handle tenant revenue management. A mall operator can tell a prospective tenant exactly how many people pass unit 14B on a Saturday afternoon, and rents reflect it. Nobody in mall leasing considers this exotic. Pharmacy chains sit on the same opportunity with their own internal real estate — and most have never zoned it, measured it, or built a rate card around it.
Strip away the vendor jargon and a sellable placement needs three metrics, consistently measured over time:
With those three, a commercial director can build a tiered rate card: prescription-adjacent zones as premium inventory, mid-store category zones at standard rates, and back-of-store positions priced honestly low — or bundled as value-adds. Suppliers respond well to this because it mirrors how they already buy digital media. The conversation shifts from "trust me, this shelf is good" to "this zone delivered this many exposures last quarter, here is the dwell profile, and here is what a placement costs."
Modern people-counting infrastructure is sensor-agnostic, meaning a chain does not need to rip out existing hardware to start zoning its stores. Vemco Group processes more than 85 million counts per day across 2,000+ customers in over 95 countries, with counting delivered anonymously and in line with GDPR — no faces, no identities, just movement and presence. Accuracy is contractually guaranteed at a minimum of 96%, and in practice typically runs at 98–99% when lighting, layout and visitor behaviour allow. That distinction matters when you are invoicing a supplier against the data: an honest accuracy floor is defensible in a commercial dispute; an inflated flat claim is not.
Latency matters more than most buyers initially assume. With counts flowing at roughly two-second latency, hosted in AWS EU-Frankfurt, a trade marketing team can see mid-campaign whether a new skincare fixture is generating stops — and reposition it within the same week rather than discovering failure in a post-campaign report. That responsiveness is itself sellable: suppliers will pay more for placements that come with in-flight optimisation.
One thing every implementer learns the hard way: the prescription-counter zone produces spectacular dwell numbers that need careful interpretation. People waiting for a prescription are stationary whether or not your fixture interests them, so raw dwell time in that zone is inflated by queue mechanics, not engagement. The fix is to benchmark each zone against its own baseline — dwell with an empty fixture versus dwell with the supplier's display — and sell the uplift, not the absolute figure. Suppliers who have been burned by inflated retail media claims elsewhere will respect this immediately, and it protects the chain's credibility when a campaign underperforms.
A related trap: staff movement. Pharmacists crossing the counter zone dozens of times a day will pollute exposure counts unless the measurement setup excludes staff paths. Get this wrong and your premium zone's numbers collapse under supplier scrutiny in month three.
The technology is the easy part. The harder work is commercial: deciding which zones become sellable inventory, agreeing measurement definitions with suppliers before campaigns start, and setting a cadence — monthly exposure reports, quarterly rate reviews. Chains that succeed here treat the first two or three supplier deals as pilots, share the data openly including the disappointing parts, and let the evidence set the price. Within a couple of cycles, the rate card stops being a negotiation and becomes a menu.
For vitamin, supplement and skincare brands, the appeal is symmetrical. These are consideration-heavy categories where in-store attention genuinely drives sales, and where digital media costs keep climbing. A measured pharmacy placement with verified exposure and dwell data is often cheaper per genuine engagement than the paid social alternative — and it sits centimetres from the point of purchase.
If you are ready to zone your stores, prove your traffic to suppliers and price prescription-adjacent placements on evidence rather than instinct, talk to the team at Vemco Group. We will show you how chains like yours turn shelf space into a measurable, invoiceable retail media channel.